Alkermes (ALKS) Change in Receivables (2010 - 2026)
Alkermes' (ALKS) quarterly Change in Receivables came in at $23.2 million in Q1 2026, up 135.27% year-on-year from $9.9 million in Q1 2025, and up 213.98% on a QoQ basis from -$20.4 million in Q4 2025.
Alkermes (ALKS) Change in Receivables (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Change in Receivables data on file, last reported at $23.2 million in Q1 2026.
- On a quarterly basis, Change in Receivables rose 135.27% year-over-year to $23.2 million in Q1 2026; TTM through Mar 2026 was $38.5 million, a 1249.84% increase from a year earlier, with the FY2025 full-year figure at -$50.5 million, down 197.02% from the prior year.
- Change in Receivables for Q1 2026 stood at $23.2 million, up from -$20.4 million in the prior quarter.
- Over the last five years, Change in Receivables for ALKS reached as high as $65.3 million in Q2 2023 and fell as low as -$65.8 million in Q1 2025.
- Historically, Change in Receivables has averaged $2.6 million across 5 years, with a median of $795000.0 in 2024.
- Across the five-year window, Change in Receivables surged 1695.8% in 2023 and sank 295.87% in 2025, its largest moves.
- Year by year, Change in Receivables stood at $30.8 million in 2022, then tumbled by 116.95% to -$5.2 million in 2023, then jumped by 431.76% to $17.3 million in 2024, then sank by 217.62% to -$20.4 million in 2025, then jumped by 213.98% to $23.2 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $23.2 million in Q1 2026, -$20.4 million in Q4 2025, and -$512000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 23.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.22 Mn |
| Mar 31, 2026 | 23.22 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -512,000.00 |
| Sep 30, 2025 | -512,000.00 |
| Jun 30, 2025 | 36.20 Mn |
| Jun 30, 2025 | 36.20 Mn |
| Mar 31, 2025 | -65.83 Mn |
| Mar 31, 2025 | -65.83 Mn |
| Dec 31, 2024 | 17.32 Mn |
| Dec 31, 2024 | 17.32 Mn |
| Sep 30, 2024 | 795,000.00 |
| Sep 30, 2024 | 795,000.00 |
| Jun 30, 2024 | 50.57 Mn |
| Jun 30, 2024 | 50.57 Mn |
| Mar 31, 2024 | -16.63 Mn |
| Mar 31, 2024 | -16.63 Mn |
| Dec 31, 2023 | -5.22 Mn |
| Dec 31, 2023 | -5.22 Mn |